|
1
|
Picci P: Osteosarcoma (osteogenic
sarcoma). Orphanet J Rare Dis. 2:62007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jones KB: Osteosarcomagenesis: Modeling
cancer initiation in the mouse. Sarcoma. 2011:6941362011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stiller CA, Craft AW and Corazziari I:
Survival of children with bone sarcoma in Europe since 1978:
Results from the EUROCARE study. Eur J Cancer. 37:760–766. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu PK, Chen WM, Chen CF, Lee OK, Haung CK
and Chen TH: Primary osteogenic sarcoma with pulmonary metastasis:
Clinical results and prognostic factors in 91 patients. Jpn J Clin
Oncol. 39:514–522. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Group TEES: ESMO/European Sarcoma Network
Working Group: Bone sarcomas: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 25(Suppl 3):
iii113–iii123. 2014. View Article : Google Scholar
|
|
7
|
Yang R, Sowers R, Mazza B, Healey JH,
Huvos A, Grier H, Bernstein M, Beardsley GP, Krailo MD, Devidas M,
et al: Sequence alterations in the reduced folate carrier are
observed in osteosarcoma tumor samples. Clin Cancer Res. 9:837–844.
2003.PubMed/NCBI
|
|
8
|
Guo W, Healey JH, Meyers PA, Ladanyi M,
Huvos AG, Bertino JR and Gorlick R: Mechanisms of methotrexate
resistance in osteosarcoma. Clin Cancer Res. 5:621–627.
1999.PubMed/NCBI
|
|
9
|
Shaikh AB, Li F, Li M, He B, He X, Chen G,
Guo B, Li D, Jiang F, Dang L, et al: Present advances and future
perspectives of molecular targeted therapy for osteosarcoma. Int J
Mol Sci. 17:5062016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma W, Nomura M, Takahashi-Nishioka T and
Kobayashi S: Combined effects of fangchinoline from Stephania
tetrandra Radix and formononetin and calycosin from Astragalus
membranaceus Radix on hyperglycemia and hypoinsulinemia in
streptozotocin-diabetic mice. Biol Pharm Bull. 30:2079–2083. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gülçin I, Elias R, Gepdiremen A, Chea A
and Topal F: Antioxidant activity of bisbenzylisoquinoline
alkaloids from Stephania rotunda: Cepharanthine and fangchinoline.
J Enzyme Inhib Med Chem. 25:44–53. 2010. View Article : Google Scholar
|
|
12
|
Guo B, Su J, Zhang T, Wang K and Li X:
Fangchinoline as a kinase inhibitor targets FAK and suppresses
FAK-mediated signaling pathway in A549. J Drug Target. 23:266–274.
2015. View Article : Google Scholar
|
|
13
|
Wang CD, Yuan CF, Bu YQ, Wu XM, Wan JY,
Zhang L, Hu N, Liu XJ, Zu Y, Liu GL, et al: Fangchinoline inhibits
cell proliferation via Akt/GSK-3beta/cyclin D1 signaling and
induces apoptosis in MDA-MB-231 breast cancer cells. Asian Pac J
Cancer Prev. 15:769–773. 2014. View Article : Google Scholar
|
|
14
|
Xing Z, Zhang Y, Zhang X, Yang Y, Ma Y and
Pang D: Fangchinoline induces G1 arrest in breast cancer cells
through cell-cycle regulation. Phytother Res. 27:1790–1794. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang N, Pan W, Zhu M, Zhang M, Hao X,
Liang G and Feng Y: Fangchinoline induces autophagic cell death via
p53/sestrin2/AMPK signalling in human hepatocellular carcinoma
cells. Br J Pharmacol. 164:731–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Y, Chen J, Wang L, Huang Y, Leng Y
and Wang G: Fangchinoline induces G0/G1 arrest by modulating the
expression of CDKN1A and CCND2 in K562 human chronic myelogenous
leukemia cells. Exp Ther Med. 5:1105–1112. 2013.PubMed/NCBI
|
|
17
|
Guo B, Xie P, Su J, Zhang T, Li X and
Liang G: Fangchinoline suppresses the growth and invasion of human
glioblastoma cells by inhibiting the kinase activity of Akt and
Akt-mediated signaling cascades. Tumour Biol. 37:2709–2719. 2016.
View Article : Google Scholar
|
|
18
|
Tian F, Ding D and Li D: Fangchinoline
targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901
cells. Int J Oncol. 46:2355–2363. 2015.PubMed/NCBI
|
|
19
|
Li D, Lu Y, Sun P, Feng LX, Liu M, Hu LH,
Wu WY, Jiang BH, Yang M, Qu XB, et al: Inhibition on proteasome β1
subunit might contribute to the anti-cancer effects of
fangchinoline in human prostate cancer cells. PLoS One.
10:e01416812015. View Article : Google Scholar
|
|
20
|
Li X, Huang T, Jiang G, Gong W, Qian H and
Zou C: Synergistic apoptotic effect of crocin and cisplatin on
osteosarcoma cells via caspase induced apoptosis. Toxicol Lett.
221:197–204. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tsai HC, Huang CY, Su HL and Tang CH: CTGF
increases drug resistance to paclitaxel by upregulating survivin
expression in human osteosarcoma cells. Biochim Biophys Acta.
1843:846–854. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang J, Yu XH, Yan YG, Wang C and Wang
WJ: PI3K/Akt signaling in osteosarcoma. Clin Chim Acta.
444:182–192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li YJ, Dong BK, Fan M and Jiang WX: BTG2
inhibits the proliferation and metastasis of osteosarcoma cells by
suppressing the PI3K/AKT pathway. Int J Clin Exp Pathol.
8:12410–12418. 2015.
|
|
24
|
Du S and Yang L: ClC-3 chloride channel
modulates the proliferation and migration of osteosarcoma cells via
AKT/GSK3β signaling pathway. Int J Clin Exp Pathol. 8:1622–1630.
2015.
|
|
25
|
Ma X, Sun W, Shen J, Hua Y, Yin F, Sun M
and Cai Z: Gelsolin promotes cell growth and invasion through the
upregulation of p-AKT and p-38 pathway in osteosarcoma. Tumour
Biol. 37:7165–7174. 2016. View Article : Google Scholar
|
|
26
|
Nakagami H, Kawamura K, Sugisaka K, Sekine
M and Shinmyo A: Phosphorylation of retinoblastoma-related protein
by the cyclin D/cyclin-dependent kinase complex is activated at the
G1/S-phase transition in tobacco. Plant Cell. 14:1847–1857. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Keenan SM, Lents NH and Baldassare JJ:
Expression of cyclin E renders cyclin D-CDK4 dispensable for
inactivation of the retinoblastoma tumor suppressor protein,
activation of E2F, and G1-S phase progression. J Biol Chem.
279:5387–5396. 2004. View Article : Google Scholar
|
|
28
|
Libra M, Scalisi A, Vella N, Clementi S,
Sorio R, Stivala F, Spandidos DA and Mazzarino C: Uterine cervical
carcinoma: Role of matrix metalloproteinases (Review). Int J Oncol.
34:897–903. 2009. View Article : Google Scholar : PubMed/NCBI
|
